They are a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Their novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. Their unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., Prostate Specific Antigen (“PSA”), digital rectal exam (“DRE”), age) used by clinicians. Their lead products address men at risk for developing prostate cancer, but in addition, they are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide their clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care. Their expertise in precision diagnostics and their portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports their active pipeline of new testing solutions for prostate and other urologic diseases.

Industry
Diagnostics - Services-commercial Physical & Biological Research

CEO	CFO
-

Employees	Founded
190	2003

Contacts

Address: Cap Business Center Zone Industrielle Des Hauts-sarts 4040 Herstal, Belgium

Telephone: +32 4 257 70 21

Web page: http://www.mdxhealth.com

IPO information

First Trade Date	11/4/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

Shares & Volumes

Shares Initial (MM)	3.75
Shares Revised (MM)	3.8
Expected offer amount (MM)	$50.48
Realized offer amount(MM)	$45.6

Financial Data (last reporting year)

Market Cap (MM)	-
Revenues (MM)	$19.31
Net Income (Loss) (MM)	$-28.25

Voting

What do you think will happen with the MDXH share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes:

The lead left underwriter: Piper Sandler

IPOs led by the firm	.Pro
Profitability of conducted IPOs ?	.Pro
1st day change ?	.Pro
Change for the first 3 months ?	.Pro

Underwriters
Piper Sandler/ Oppenheimer & Co./ BTIG/ KBC Securities
CO-Managers

Sector: Healthcare

Tweets about $MDXH

Tweets
Tweets volume

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats

Interest over time
Interest by region

Mdxhealth, Inc. (MDXH)

Buy Bitcoin

Free full financial analysis

IPO Pro-version